Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of safety and efficacy of colon cancer stem cell target immunotherapy

ABSTRACT: Interventions: OR7C1+IFNb BORIS+IFNb OR7C1+IFNa BORIS+IFNa Primary outcome(s): 1) Safety 2) Immunological response Study Design: Parallel Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2649618 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

Project description: Not available

| S-EPMC7260689 | biostudies-literature

Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study.

Project description: Not available

| S-EPMC7527748 | biostudies-literature

Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE.

Project description: Not available

| S-EPMC5908387 | biostudies-literature

Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.

Project description: Not available

| S-EPMC7994724 | biostudies-literature

Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy.

Project description: Not available

| S-EPMC5746145 | biostudies-literature

ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis.

Project description: Not available

| S-EPMC9237783 | biostudies-literature

Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.

Project description: Not available

| S-EPMC9236084 | biostudies-literature

Tripartite target-agnostic combination immunotherapy cures established poorly immunogenic tumors

Project description:Single-agent immunotherapy, such as immune checkpoint inhibition, has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to suppress the host anti-tumor immune response reducing the efficacy of single-agent immunotherapy. Combination immunotherapy approaches that are effective in such poorly immunogenic tumors mostly rely on precise knowledge of immunological targets on tumor cells by vaccinations or antibodies engineered to directly target those. Thus, creating a target-agnostic combination immunotherapy that is effective in poorly immunogenic tumors for which an immunological target is not known is a major challenge. We show that combined adoptive cellular therapy (ACT) with lymphokine-activated killer cells (LAKs), cytokine-induced killer cells (CIKs), Vγ9Vδ2-T-cells (γδ-T-cells) and adaptive, tumor-specific T-cells (CTLs) display synergistic anti-tumor treatment effects, which is further enhanced by co-treatment with anti-PD1 antibodies. Most strikingly, combination of this ACT with anti-PD1 antibodies, local immunotherapy of agonists against Toll-like receptor 3, 7 and 9 and pre-ACT lymphodepletion, a protocol we named TRI-IT, eradicates established, poorly immunogenic tumors and induces durable anti-tumor immunity in a variety of poorly immunogenic syngeneic, autochthonous, as well as autologous humanized patient-derived models. Mechanistically, we show that TRI-IT co-activates adaptive cellular and humoral, as well as innate anti-tumor immune responses to mediate its anti-tumor effect without inducing off-target toxicity. Our data demonstrate the efficacy of a target-agnostic combination immunotherapy that eradicates and potentially cures established poorly immunogenic tumors.

2022-10-28 | GSE173107 | GEO

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.

Project description: Not available

| S-EPMC8151051 | biostudies-literature

Can immunotherapy specifically target acute myeloid leukemic stem cells?

Project description: Not available

| S-EPMC3601163 | biostudies-literature